Telomir Pharmaceuticals Inc (TELO)

$1.29 +0.08 (6.61%)
Market Cap 41.60M
Revenue (ttm) 0.00
Net Income (ttm) -16.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 122,800
Avg Vol 168,832
Day's Range N/A - N/A
Shares Out 34.38M
Stochastic %K 89%
Beta -0.49
Analysts Strong Sell
Price Target $15.50

Company Profile

Telomir Pharmaceuticals, Inc., a preclinical-stage biotechnology company, focuses on reversing biological aging and degenerative diseases. It is developing Telomir-1, an oral small molecule metal ion regulator designed to protect against age-related conditions, including Progeria, Wilson's disease, and age-related macular degeneration (amd), as well as type 2 diabetes, cancer, and Alzheimer's disease. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharma...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 396 6723
Address:
100 SE 2nd Street, Suite 2000 #1009, Miami, United States
yikobe
yikobe Feb. 26 at 4:20 AM
$TELO The stock surged 6% for two consecutive days with very low trading volume. I believe the big players have locked up the float. What’s your price target?
1 · Reply
Tristan2024
Tristan2024 Feb. 25 at 4:51 PM
$TELO something cooking….
1 · Reply
Washingtonstate
Washingtonstate Feb. 25 at 4:30 PM
$TELO
0 · Reply
PF_Goodrich
PF_Goodrich Feb. 25 at 2:38 PM
$TELO thats whats she said
0 · Reply
RaphaelRapoport
RaphaelRapoport Feb. 24 at 10:44 PM
$TELO we finally going to get that release???
1 · Reply
Tristan2024
Tristan2024 Feb. 24 at 7:04 PM
$TELO hello….:-)
0 · Reply
Tristan2024
Tristan2024 Feb. 23 at 1:22 PM
$TELO what’s happening?
0 · Reply
elkmed
elkmed Feb. 21 at 6:04 AM
$RGC at one moment it went from 0.7 to above 70$. 100x the price. 1000$ become a 100000. How big chance $TELO will be next one, I have dream it will go to above 300$.
1 · Reply
elkmed
elkmed Feb. 21 at 5:59 AM
$ABVX one year ago it was below 10. Next big one for coming year will be $TELO keep in your list
0 · Reply
Tristan2024
Tristan2024 Feb. 20 at 6:10 PM
$TELO $2 EOD
0 · Reply
Latest News on TELO
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

Feb 17, 2026, 8:00 AM EST - 8 days ago

Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models

Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging

Feb 5, 2026, 8:00 AM EST - 20 days ago

Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

Jan 5, 2026, 8:00 AM EST - 7 weeks ago

Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

Dec 18, 2025, 7:30 AM EST - 2 months ago

Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

Nov 25, 2025, 8:00 AM EST - 3 months ago

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells

Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells

Nov 21, 2025, 7:30 AM EST - 3 months ago

Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells

Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line

Nov 12, 2025, 8:00 AM EST - 3 months ago

Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo

Oct 23, 2025, 7:30 AM EDT - 4 months ago

Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo

Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth

Oct 21, 2025, 7:30 AM EDT - 4 months ago

Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth

Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer

Oct 14, 2025, 8:00 AM EDT - 4 months ago

Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer

Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug

Oct 9, 2025, 2:35 PM EDT - 4 months ago

Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

Oct 9, 2025, 7:30 AM EDT - 5 months ago

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance

Oct 7, 2025, 7:30 AM EDT - 5 months ago

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies

Sep 18, 2025, 8:00 AM EDT - 5 months ago

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy

Sep 9, 2025, 8:00 AM EDT - 6 months ago

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy

Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases

Aug 28, 2025, 8:00 AM EDT - 6 months ago

Telomir Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation Pathways in Cancer, Aging, and Age-Related Diseases

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction

Aug 7, 2025, 8:00 AM EDT - 7 months ago

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Inhibits Key Epigenetic Enzymes Driving Tumor Growth, Autoimmune Disease, Neurodegeneration, and Metabolic Dysfunction

Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's

Jul 24, 2025, 8:00 AM EDT - 7 months ago

Telomir Pharmaceuticals Reports Telomir-1's Unique Profile Restores Mitochondrial Health While Improving Oxidative Stress Without Promoting Cell Proliferation in Diseased Human Cell Lines Highlighting Potential Relevance to Neurodegenerative Pathways in Alzheimer's and Parkinson's

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

Jul 18, 2025, 8:00 AM EDT - 7 months ago

Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

Jun 18, 2025, 9:15 AM EDT - 9 months ago

Telomir Pharmaceuticals Prevents Cellular Aging in Patient-Derived Cells from Children with Progeria - an Ultra-Rare Genetic Disorder that Causes Rapid Aging

Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model

Jun 11, 2025, 9:30 AM EDT - 9 months ago

Telomir Pharmaceuticals Announces Telomir-1 Demonstrates Dose-Dependent Restoration of Neurological, Liver and Kidney Functions in Preclinical Wilson's Disease Model

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

Jun 5, 2025, 8:30 AM EDT - 9 months ago

Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

Jun 2, 2025, 8:30 AM EDT - 9 months ago

Telomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity Platform

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints

May 29, 2025, 8:30 AM EDT - 9 months ago

Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate Endpoints

Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND

May 21, 2025, 9:00 AM EDT - 10 months ago

Telomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease IND

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity

May 15, 2025, 8:00 AM EDT - 10 months ago

Telomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market Opportunity

Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia

May 7, 2025, 8:00 AM EDT - 10 months ago

Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Telomir Pharmaceuticals Announces Significant Anti-Cancer Effects in Prostate Cancer Animal Model Using Highly Aggressive Human Prostate Cancer Cells

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

Feb 26, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines

Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

Feb 21, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market

Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

Feb 18, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)

Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses

Jan 28, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses

Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

Jan 7, 2025, 8:00 AM EST - 1 year ago

Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in Preclinical Model of Progeria (A Rare Genetic Disorder Causing Rapid Aging)

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

Dec 23, 2024, 7:30 AM EST - 1 year ago

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Dec 12, 2024, 8:30 AM EST - 1 year ago

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price

Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?

Dec 3, 2024, 1:40 PM EST - 1 year ago

Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

Dec 3, 2024, 7:30 AM EST - 1 year ago

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

Nov 21, 2024, 7:00 AM EST - 1 year ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1

Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday

Sep 26, 2024, 4:00 PM EDT - 1 year ago

Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs

Aug 20, 2024, 7:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs

Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

Aug 12, 2024, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Mourns the Passing of Chairman and CEO Dr. Christopher Chapman

Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

Jun 17, 2024, 4:10 PM EDT - 1 year ago

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

May 30, 2024, 8:30 AM EDT - 1 year ago

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Apr 16, 2024, 8:30 AM EDT - 2 years ago

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

Apr 2, 2024, 8:30 AM EDT - 2 years ago

Telomir Pharmaceuticals' Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Mar 29, 2024, 4:44 PM EDT - 2 years ago

UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Mar 26, 2024, 8:30 AM EDT - 2 years ago

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Mar 22, 2024, 8:30 AM EDT - 2 years ago

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

yikobe
yikobe Feb. 26 at 4:20 AM
$TELO The stock surged 6% for two consecutive days with very low trading volume. I believe the big players have locked up the float. What’s your price target?
1 · Reply
Tristan2024
Tristan2024 Feb. 25 at 4:51 PM
$TELO something cooking….
1 · Reply
Washingtonstate
Washingtonstate Feb. 25 at 4:30 PM
$TELO
0 · Reply
PF_Goodrich
PF_Goodrich Feb. 25 at 2:38 PM
$TELO thats whats she said
0 · Reply
RaphaelRapoport
RaphaelRapoport Feb. 24 at 10:44 PM
$TELO we finally going to get that release???
1 · Reply
Tristan2024
Tristan2024 Feb. 24 at 7:04 PM
$TELO hello….:-)
0 · Reply
Tristan2024
Tristan2024 Feb. 23 at 1:22 PM
$TELO what’s happening?
0 · Reply
elkmed
elkmed Feb. 21 at 6:04 AM
$RGC at one moment it went from 0.7 to above 70$. 100x the price. 1000$ become a 100000. How big chance $TELO will be next one, I have dream it will go to above 300$.
1 · Reply
elkmed
elkmed Feb. 21 at 5:59 AM
$ABVX one year ago it was below 10. Next big one for coming year will be $TELO keep in your list
0 · Reply
Tristan2024
Tristan2024 Feb. 20 at 6:10 PM
$TELO $2 EOD
0 · Reply
RaphaelRapoport
RaphaelRapoport Feb. 20 at 2:58 PM
$TELO let’s get Pr and back to $2
0 · Reply
PortfolioSovereign
PortfolioSovereign Feb. 20 at 2:22 PM
$TELO Telomir Pharmaceuticals develops anti-aging therapies. Early-stage risk dominates valuation. Clinical validation is required.
0 · Reply
yikobe
yikobe Feb. 20 at 2:43 AM
$TELO https://www.sec.gov/Archives/edgar/data/1971532/000149315226007487/formdefm14a.htm
0 · Reply
yikobe
yikobe Feb. 19 at 2:56 AM
$TELO when def release?
0 · Reply
Washingtonstate
Washingtonstate Feb. 18 at 8:32 PM
$TELO
0 · Reply
moneymaker15
moneymaker15 Feb. 18 at 4:03 PM
$TELO So this NDA should be submitted anytime now and ending March....
0 · Reply
Tristan2024
Tristan2024 Feb. 18 at 12:01 PM
$TELO
0 · Reply
kdretirein10
kdretirein10 Feb. 17 at 5:45 PM
$TELO here we are again today, Telomir posts another update on cancer news that this company has been conducting in pre-clinical trials. Normally in the past this news would have resulted in an increased price and everyone is would happy. However, the response to today's PR post did not yield the desired results and only increased price by $.04 cents and volume of 54,027. Once this company announces the NDA being filed with the FDA this stock will soar temporarily. Other than that, this company is going to struggle unless they turn their public relations department around and get Telomir-1 out of pre-clinical trials.
0 · Reply
RaphaelRapoport
RaphaelRapoport Feb. 17 at 3:27 PM
$TELO This needs to move way more.
0 · Reply
Tristan2024
Tristan2024 Feb. 17 at 1:24 PM
$TELO https://x.com/uscorpfilings/status/2023748081754513457?s=46
0 · Reply
Tristan2024
Tristan2024 Feb. 17 at 1:12 PM
$TELO https://x.com/accesswirenews/status/2023744628394975356?s=46 PT $5
0 · Reply
Tristan2024
Tristan2024 Feb. 17 at 1:04 PM
$TELO
0 · Reply